Metoprolol Retard Viatris  23.75 mg tabl. prol.-rel. বেলজিয়াম - ইংরেজি - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

metoprolol retard viatris 23.75 mg tabl. prol.-rel.

viatris gx bv-srl - metoprolol succinate 23,75 mg - eq. metoprolol tartrate 25 mg - prolonged-release tablet - 23,75 mg - metoprolol succinate 23.75 mg - metoprolol

Selozok 25 23.75 mg tabl. prol.-rel. বেলজিয়াম - ইংরেজি - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

selozok 25 23.75 mg tabl. prol.-rel.

recordati ireland ltd. - metoprolol succinate 23,75 mg - prolonged-release tablet - 23,75 mg - metoprolol succinate 23.75 mg - metoprolol

23.4% SODIUM CHLORIDE INJECTION USP SOLUTION কানাডা - ইংরেজি - Health Canada

23.4% sodium chloride injection usp solution

baxter corporation - sodium chloride - solution - 23.4% - sodium chloride 23.4% - replacement preparations

AFT - Metoprolol CR নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

aft - metoprolol cr

aft pharmaceuticals ltd - metoprolol succinate 23.75mg; metoprolol succinate 23.75mg; metoprolol succinate 23.75mg - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

Pneumovax 23 সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

pneumovax 23

msd pharma (singapore) pte. ltd. - pneumococcal polysaccharides 23 most prevalent types - injection - 25mcg/0.5ml each - pneumococcal polysaccharides 23 most prevalent types 25mcg/0.5ml each

Taxespira (previously Docetaxel Hospira UK Limited ) ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

taxespira (previously docetaxel hospira uk limited )

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

METROL-XL 23.75 metoprolol succinate 23.75 mg modified release tablet blister pack অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

metrol-xl 23.75 metoprolol succinate 23.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: titanium dioxide; glycerol; magnesium stearate; microcrystalline cellulose; stearic acid; ethylcellulose; maize starch; hypromellose; methylcellulose - stable, chronic heart failure as an adjunct to other heart failure therapy.

OLICLINOMEL N7-1000 E 2500 mL IV emulsion for infusion with electrolytes bag অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

oliclinomel n7-1000 e 2500 ml iv emulsion for infusion with electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: glycerol; sodium hydroxide; ascorbyl palmitate; egg lecithin; sodium oleate; water for injections - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N7-1000 2500mL IV emulsion for infusion without electrolytes bag অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

oliclinomel n7-1000 2500ml iv emulsion for infusion without electrolytes bag

baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: water for injections; egg lecithin; ascorbyl palmitate; sodium hydroxide; glycerol; sodium oleate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.